Ketones as Brain Fuel When Glucose Fails in Alzheimer's and Cognitive Decline

This discussion between Peter Attia and metabolic researcher Dominic D'Agostino explores ketogenic therapies as potential treatments for Alzheimer's disease and cognitive decline. The conversation is particularly relevant given the limited success and high costs of current Alzheimer's drugs, including antibody therapies that can cost hundreds of thousands of dollars with serious side effects like cerebral hemorrhage.

D'Agostino reframes Alzheimer's as primarily an energy crisis rather than a single disease process. He emphasizes that glucose hypometabolism - the brain's reduced ability to use glucose - is now a diagnostic criterion for dementia. Rather than viewing amyloid and tau proteins as primary causes, he argues they're downstream consequences of systemic inflammation that leads to neuroinflammation. This perspective shifts focus toward metabolic interventions.

Ketogenic therapies offer multiple therapeutic mechanisms: providing alternative brain fuel through ketones, dramatically reducing systemic inflammation, and improving overall brain energy metabolism. D'Agostino notes his own inflammatory markers are undetectable on a ketogenic diet. Research shows that while brain glucose utilization declines with age, the ability to use ketones remains preserved, providing a strong rationale for ketone-based interventions.

Clinical applications show promise but require nuanced approaches. Acute studies demonstrate cognitive improvements when ketones are elevated, though long-term trials tracking amyloid progression are still ongoing. Patient selection appears crucial - those with significant glucose hypometabolism may be the best candidates. D'Agostino advocates for comprehensive metabolic formulas combining ketones with compounds like MCT oil, creatine, alpha-GPC, and caffeine rather than single interventions, though funding agencies typically resist supporting multi-component approaches.